Lilly beats Wall Street estimates on injectable GLP-1 sales
The company points to retatrutide's completed clinical data package and new manufacturing capacity as the next phase of its obesity franchise.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 6 03:00 ETSource: Pharmaceutical Executive
The wire
- 01Eli Lilly reported quarterly results above Wall Street estimates, driven by its injectable GLP-1 medicines, according to Pharmaceutical Executive.
- 02Incretin demand continues to underwrite Lilly's manufacturing expansion, which bears directly on supply for prescribers and pharmacies.
- 03Lilly says retatrutide's complete clinical data package is in hand; no filing date, pricing or launch timing was given in the statement.
From the source
Read at pharmexec.comEli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs
"At the same time, Lilly is building for the future. With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter."
